Profile data is unavailable for this security.
About the company
Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
- Revenue in USD (TTM)25.97m
- Net income in USD-37.31m
- Incorporated2013
- Employees144.00
- LocationZomedica Corp100 Phoenix Drive, Suite 125ANN ARBOR 48108United StatesUSA
- Phone+1 (734) 369-2555
- Fax+1 (780) 440-1377
- Websitehttps://zomedica.com/
Mergers & acquisitions
| Acquired company | ZOM:ASQ since announced | Transaction value |
|---|---|---|
| Qorvo Biotechnologies LLC | -6.25% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Oncology Network Inc | 1.34bn | -15.48m | 75.38m | 1.53k | -- | -- | -- | 0.0563 | -2.07 | -2.07 | 161.04 | -9.94 | 3.53 | 33.53 | 9.26 | 878,552.80 | -22.82 | -- | -78.96 | -- | 5.00 | -- | -6.46 | -- | 1.20 | -7.84 | 0.606 | -- | 11.27 | -- | -- | -- | -- | -- |
| Cardiff Lexington Corp | 11.65m | 2.36m | 91.14m | 10.00 | 0.4311 | -- | 38.23 | 7.82 | 16.24 | 11.60 | 10.18 | 0.6702 | 0.6319 | -- | 1.05 | 1,165,444.00 | 16.04 | -- | 52.14 | -- | 69.75 | 62.01 | 25.39 | -- | -- | 2.66 | 0.5106 | -- | -- | 39.71 | -- | -- | -- | -- |
| American Well Corp | 254.57m | -349.58m | 139.54m | 1.10k | -- | 1.05 | -- | 0.5481 | -24.39 | -24.39 | 17.73 | 8.87 | 0.364 | 22.20 | 3.73 | 230,587.00 | -50.22 | -28.25 | -61.56 | -32.66 | 34.52 | 40.51 | -137.98 | -121.27 | 3.76 | -- | 0.00 | -- | -6.55 | 17.85 | -149.66 | -- | 51.49 | -- |
| Zomedica Corp | 25.97m | -37.31m | 146.99m | 144.00 | -- | 0.6339 | -- | 5.66 | -0.0381 | -0.0381 | 0.0265 | 0.2366 | 0.0992 | 2.14 | 13.17 | 180,319.40 | -14.26 | -14.03 | -14.73 | -14.45 | 67.78 | -- | -143.67 | -220.98 | 10.87 | -- | 0.00 | -- | 33.05 | -- | -102.93 | -- | 89.85 | -- |
| DLH Holdings Corp | 402.59m | 3.07m | 165.39m | 3.20k | 58.97 | 1.55 | 8.18 | 0.4108 | 0.197 | 0.197 | 27.68 | 7.50 | 1.17 | -- | 6.57 | 125,807.80 | 0.8924 | 5.38 | 1.11 | 7.20 | 20.92 | 20.56 | 0.7631 | 3.41 | -- | 1.50 | 0.6069 | 0.00 | -4.88 | 23.05 | -93.73 | -28.16 | -0.903 | -- |
| Longduoduo Co Ltd | 8.78m | 1.77m | 173.13m | -- | 97.70 | 434.98 | 83.55 | 19.73 | 0.0591 | 0.0591 | 0.2923 | 0.0133 | 5.06 | 453.60 | 134.94 | -- | 114.14 | -- | -- | -- | 95.04 | -- | 22.55 | -- | 1.04 | -- | 0.00 | -- | 17.93 | -- | 99.48 | -- | -- | -- |
| Biodesix Inc | 54.85m | -47.06m | 189.23m | 217.00 | -- | -- | -- | 3.45 | -0.5465 | -0.5465 | 0.6308 | -0.0566 | 0.653 | -- | 7.42 | 252,760.40 | -56.02 | -55.60 | -82.08 | -80.94 | 76.27 | 59.53 | -85.80 | -105.15 | -- | -3.71 | 1.18 | -- | 28.46 | 19.16 | 20.32 | -- | 106.31 | -- |
| Joint Corp | 119.12m | -11.13m | 213.53m | 444.00 | -- | 8.14 | -- | 1.79 | -0.7556 | -0.7556 | 8.04 | 1.75 | 1.29 | -- | 35.08 | 268,283.10 | -12.01 | 4.32 | -17.55 | 6.05 | 90.94 | 90.28 | -9.34 | 3.68 | -- | 1,198.66 | 0.0022 | -- | 16.24 | 26.27 | -1,656.09 | -- | 35.09 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 47.96m | 4.89% |
| Geode Capital Management LLCas of 31 Mar 2024 | 10.12m | 1.03% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 9.86m | 1.01% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.11m | 0.32% |
| Brown Brothers Harriman & Co. (Investment Management)as of 31 Mar 2024 | 2.47m | 0.25% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 1.80m | 0.18% |
| Atom Investors LPas of 31 Mar 2024 | 1.20m | 0.12% |
| T. Rowe Price International Ltd.as of 31 Mar 2024 | 948.30k | 0.10% |
| Citadel Securities LLCas of 31 Mar 2024 | 743.11k | 0.08% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 412.33k | 0.04% |
